Trade CLYM stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Climb Bio, Inc. (CLYM) is trading at US$10.86, up 1.40% today as of Oct 8, 16:00 EDT. The company has a market capitalisation of US$992.5M. Over the past 52 weeks, CLYM has traded between US$1.64 and US$18.33. On Syfe you can trade CLYM with $0 commission and add it to your watchlist.
| Previous close | US$10.71 |
|---|---|
| Market cap | US$992.5M |
| 52-week range | US$1.64 – US$18.33 |
| Volume | 1.07M |
| Exchange | US |
Climb Bio, Inc.
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Year: 2021
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating
Sep 8, 1:24 PM · MT Newswires
Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says
Sep 4, 3:17 PM · MT Newswires
B. Riley Adjusts Price Target on Climb Bio to $30 From $26, Maintains Buy Rating
Sep 4, 12:14 PM · MT Newswires
Update: Climb Bio Shares Fall After Early Phase 1 Data for IgA Nephropathy Drug
Sep 3, 6:18 PM · MT Newswires
Wedbush Adjusts Price Target on Climb Bio to $25 From $20, Keeps Outperform Rating
Sep 3, 3:23 PM · MT Newswires
Climb Bio, Inc. (CLYM) stock is trading at US$10.86, +1.40% from the previous close of US$10.71.
The market cap for Climb Bio, Inc. (CLYM) stock is approximately US$992.5M.
The 52-week high for Climb Bio, Inc. (CLYM) stock is US$18.33.
The 52-week low for Climb Bio, Inc. (CLYM) stock is US$1.64.
Climb Bio, Inc. (CLYM) does not currently pay a dividend.
Stay on top of CLYM
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
